TLDR: A new AI system developed by Bioptic.io uses LLM-based agents to significantly improve and accelerate competitive landscape mapping for drug assets in biotech due diligence. By transforming unstructured memos into a structured evaluation corpus and employing a “Competitor-Validator” agent, the system achieves 83% recall (outperforming other leading AI systems) and reduces analyst turnaround time by 20x, providing more comprehensive and precise insights into drug competitors.
In the fast-paced world of biotech and pharmaceutical investment, understanding the competitive landscape for a new drug asset is paramount. This crucial step, known as competitive landscape mapping, forms the bedrock of patent, business, and scientific due diligence. However, this process has traditionally been a manual, time-consuming, and complex endeavor, relying heavily on expert workflows and spreadsheets. Information is often scattered across various sources, riddled with aliases, and constantly changing, leading to risks in completeness, recency, and decision-making.
A recent research paper titled “LLM-Based Agents for Competitive Landscape Mapping in Drug Asset Due Diligence” by Alisa Vinogradova, Vlad Vinogradov, and their colleagues from Bioptic.io introduces a groundbreaking AI system designed to streamline this process. The paper details an agentic AI system that significantly accelerates and improves the accuracy of identifying competing drugs for a specific medical indication.
The Challenge with Traditional Methods
Identifying all competitors for a drug involves sifting through vast amounts of data from press releases, scientific literature, patents, clinical trial registries, and target-space intelligence. This information is often fragmented, paywalled, and inconsistent, making it incredibly difficult for human analysts to ensure a comprehensive and up-to-date view. Current general-purpose AI systems also struggle with the nuances of this task, often failing to reliably retrieve all relevant drug names or suffering from hallucinations (generating incorrect information).
Bioptic.io’s Innovative AI Agent System
To address these challenges, the researchers developed a specialized AI system featuring a competitor-discovery agent. This agent, when given a specific medical indication, is designed to retrieve all drugs that constitute the competitive landscape for that indication and extract their key attributes. A unique aspect of this system is its ability to learn from real-world data. The team transformed five years of multi-modal, unstructured diligence memos from a private biotech VC fund into a structured evaluation dataset. This rich, domain-specific data allowed them to train and benchmark their agents effectively.
Ensuring Accuracy with a “Competitor-Validator”
One of the most critical innovations presented in the paper is the “Competitor-Validator” agent. This LLM-as-a-judge agent acts as a crucial filtering layer, sifting out false positives from the list of predicted competitors. Its role is to maximize precision and suppress any incorrect or hallucinated drug names, ensuring that the final output is highly reliable. The validator achieves impressive performance, with a 90.4% precision and 85.7% recall on its test set, demonstrating its effectiveness in maintaining high data quality.
Remarkable Performance and Impact
The results of this new system are compelling. On their custom benchmark, the competitor-discovery agent achieved an 83% recall rate, significantly outperforming other leading AI systems like OpenAI Deep Research (65%) and Perplexity Labs (60%). Beyond raw performance metrics, the system has demonstrated a profound impact in real-world applications. In a case study with a biotech VC investment fund, the time analysts spent on competitive analysis for a drug asset dropped dramatically from approximately 2.5 days to just about 3 hours – a staggering 20-fold increase in efficiency. Furthermore, the system not only matched expert-identified competitors but also surfaced additional relevant drug assets that were previously unseen by analysts, enhancing discovery power without sacrificing precision.
How the Agents Work (Simplified)
The system employs a multi-agent approach. It starts with a hierarchical parser that reads both text and images from diligence memos, systematically extracting drug assets, indications, and then competitor drugs. For each identified drug, an attributes parser extracts details like drug name aliases, mechanism of action, development stage, and company information. The core of the competitor-discovery agent leverages advanced LLM scaffolding frameworks like REACT (Reasoning and Acting) and REFLEXION, which enable multi-step reasoning and tool use, including web browsing. This allows the agents to dynamically build on intermediate findings, formulate targeted web queries, and synthesize information from various authoritative sources like clinical trial registries and regulatory filings.
Also Read:
- AI Agents and Retrieval-Augmented Generation Revolutionize Medical Diagnosis Accuracy
- Agentic AI Transforms Financial Services: DocuAgentIQ Drives Efficiency in SBA & CRE Lending
A Leap Forward for Drug Due Diligence
This research marks a significant step forward in applying AI to complex, high-stakes tasks in the pharmaceutical industry. By combining high-recall web agents with a precision-focused LLM-as-a-judge, Bioptic.io has created a robust, domain-grounded system that addresses critical pain points in drug asset due diligence. The ability to quickly and accurately map competitive landscapes empowers investors and drug developers to make more informed decisions, ultimately accelerating the development of life-saving treatments. For more details, you can read the full research paper here.
